5th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference

The 5th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference is organized by MarketsandMarkets Conferences and will be held from Mar 07 - 08, 2024 at Park Plaza Victoria London, London, England, United Kingdom.

Leveraging next-gen technologies beyond conventional biomarker drug discovery

The emergence of the need for the safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought-after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation, and unconventional design of clinical trials.

• 20+ experts from academia and industry will be presenting their current work in Biomarkers, the Latest updates on regulatory guidelines and approvals, Cancer biomarker validation for clinical application, Challenges in NGS-based CDx, and the Importance of imaging biomarkers for precision medicine.
• Opportunity to develop long-lasting business relationships and networking opportunities with senior peers. Get the Opportunity to get your queries handled by Biomarker experts in one one-on-one session.
• Facilitated networking sessions to ensure quality interactions along with Case studies from experts who have successfully created and developed a biomarker

This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine, and Big Data. Regarding the commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers.

Key Highlights:

• Clinical biomarker identification and qualification
• Biomarkers and personalized medicine
• Assay development and validation
• NGS and novel technologies in biomarker discovery
• Commercialization of biomarkers in therapeutic and CDx applications